The challenge and promise of anti-epileptic therapy development in animal models

Michele Simonato, Amy R. Brooks-Kayal, Jerome Engel, Aristea S. Galanopoulou, Frances E. Jensen, Solomon L. Moshe, Terence J. O'Brien, Asla Pitkanen, Karen S. Wilcox, Jacqueline A. French

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Translation of successful target and compound validation studies into clinically effective therapies is a major challenge, with potential for costly clinical trial failures. This situation holds true for the epilepsies-complex diseases with different causes and symptoms. Although the availability of predictive animal models has led to the development of effective antiseizure therapies that are routinely used in clinical practice, showing that translation can be successful, several important unmet therapeutic needs still exist. Available treatments do not fully control seizures in a third of patients with epilepsy, and produce substantial side-effects. No treatment can prevent the development of epilepsy in at-risk patients or cure patients with epilepsy. And no specific treatment for epilepsy-associated comorbidities exists. To meet these demands, a redesign of translational approaches is urgently needed.

Original languageEnglish (US)
Pages (from-to)949-960
Number of pages12
JournalThe Lancet Neurology
Volume13
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Animal Models
Epilepsy
Therapeutics
Validation Studies
Comorbidity
Seizures
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

The challenge and promise of anti-epileptic therapy development in animal models. / Simonato, Michele; Brooks-Kayal, Amy R.; Engel, Jerome; Galanopoulou, Aristea S.; Jensen, Frances E.; Moshe, Solomon L.; O'Brien, Terence J.; Pitkanen, Asla; Wilcox, Karen S.; French, Jacqueline A.

In: The Lancet Neurology, Vol. 13, No. 9, 2014, p. 949-960.

Research output: Contribution to journalArticle

Simonato, M, Brooks-Kayal, AR, Engel, J, Galanopoulou, AS, Jensen, FE, Moshe, SL, O'Brien, TJ, Pitkanen, A, Wilcox, KS & French, JA 2014, 'The challenge and promise of anti-epileptic therapy development in animal models', The Lancet Neurology, vol. 13, no. 9, pp. 949-960. https://doi.org/10.1016/S1474-4422(14)70076-6
Simonato, Michele ; Brooks-Kayal, Amy R. ; Engel, Jerome ; Galanopoulou, Aristea S. ; Jensen, Frances E. ; Moshe, Solomon L. ; O'Brien, Terence J. ; Pitkanen, Asla ; Wilcox, Karen S. ; French, Jacqueline A. / The challenge and promise of anti-epileptic therapy development in animal models. In: The Lancet Neurology. 2014 ; Vol. 13, No. 9. pp. 949-960.
@article{73c4c266846848a3acfdd2e76dcf0af6,
title = "The challenge and promise of anti-epileptic therapy development in animal models",
abstract = "Translation of successful target and compound validation studies into clinically effective therapies is a major challenge, with potential for costly clinical trial failures. This situation holds true for the epilepsies-complex diseases with different causes and symptoms. Although the availability of predictive animal models has led to the development of effective antiseizure therapies that are routinely used in clinical practice, showing that translation can be successful, several important unmet therapeutic needs still exist. Available treatments do not fully control seizures in a third of patients with epilepsy, and produce substantial side-effects. No treatment can prevent the development of epilepsy in at-risk patients or cure patients with epilepsy. And no specific treatment for epilepsy-associated comorbidities exists. To meet these demands, a redesign of translational approaches is urgently needed.",
author = "Michele Simonato and Brooks-Kayal, {Amy R.} and Jerome Engel and Galanopoulou, {Aristea S.} and Jensen, {Frances E.} and Moshe, {Solomon L.} and O'Brien, {Terence J.} and Asla Pitkanen and Wilcox, {Karen S.} and French, {Jacqueline A.}",
year = "2014",
doi = "10.1016/S1474-4422(14)70076-6",
language = "English (US)",
volume = "13",
pages = "949--960",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - The challenge and promise of anti-epileptic therapy development in animal models

AU - Simonato, Michele

AU - Brooks-Kayal, Amy R.

AU - Engel, Jerome

AU - Galanopoulou, Aristea S.

AU - Jensen, Frances E.

AU - Moshe, Solomon L.

AU - O'Brien, Terence J.

AU - Pitkanen, Asla

AU - Wilcox, Karen S.

AU - French, Jacqueline A.

PY - 2014

Y1 - 2014

N2 - Translation of successful target and compound validation studies into clinically effective therapies is a major challenge, with potential for costly clinical trial failures. This situation holds true for the epilepsies-complex diseases with different causes and symptoms. Although the availability of predictive animal models has led to the development of effective antiseizure therapies that are routinely used in clinical practice, showing that translation can be successful, several important unmet therapeutic needs still exist. Available treatments do not fully control seizures in a third of patients with epilepsy, and produce substantial side-effects. No treatment can prevent the development of epilepsy in at-risk patients or cure patients with epilepsy. And no specific treatment for epilepsy-associated comorbidities exists. To meet these demands, a redesign of translational approaches is urgently needed.

AB - Translation of successful target and compound validation studies into clinically effective therapies is a major challenge, with potential for costly clinical trial failures. This situation holds true for the epilepsies-complex diseases with different causes and symptoms. Although the availability of predictive animal models has led to the development of effective antiseizure therapies that are routinely used in clinical practice, showing that translation can be successful, several important unmet therapeutic needs still exist. Available treatments do not fully control seizures in a third of patients with epilepsy, and produce substantial side-effects. No treatment can prevent the development of epilepsy in at-risk patients or cure patients with epilepsy. And no specific treatment for epilepsy-associated comorbidities exists. To meet these demands, a redesign of translational approaches is urgently needed.

UR - http://www.scopus.com/inward/record.url?scp=84906280998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906280998&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(14)70076-6

DO - 10.1016/S1474-4422(14)70076-6

M3 - Article

C2 - 25127174

AN - SCOPUS:84906280998

VL - 13

SP - 949

EP - 960

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 9

ER -